Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
CSL (CSL.AX) reported revenue of $7.30B in Q2 2026.
Prefer Sterling in Google
Add sterlingcharts.com as a preferred source so our charts can appear with a preferred badge in Google Top Stories, AI Mode, and AI Overviews.
Register for a premium account to gain access to Sterling AI.
Get StartedThings you can ask Sterling:
CSL (CSL.AX) reported revenue of $7.30B in Q2 2026.
CSLAustralian plasma and vaccines group. Seqirus is the number-two global flu manufacturer (cell-based Flucelvax, adjuvanted Fluad) and a pandemic-flu contract holder.
CSL (CSL.AX) is a Biotechnology company. Australian plasma and vaccines group. Seqirus is the number-two global flu manufacturer (cell-based Flucelvax, adjuvanted Fluad) and a pandemic-flu contract holder. It was founded in 1916, is headquartered in Melbourne, Australia and employs about 32,000 people.
Track CSL's quarterly and annual revenue, gross and net margins, and EPS in the interactive charts on this page. Data last updated October 3, 2026.
Sterling groups CSL in the Vaccines industry, alongside GSK (GSK), Pfizer (PFE), Merck & Co. (MRK), Sanofi (SNY), Moderna (MRNA) and BioNTech (BNTX).
If you are researching CSL, also look at GSK (GSK), Pfizer (PFE) and Merck & Co. (MRK). You can compare all of them side by side or browse the full Vaccines industry on Sterling.
H2 2016-H1 2026
H2 2016-H1 2026